SB
AQST icon

Samsara BioCapital’s Aquestive Therapeutics AQST Stock Holding History

Samsara BioCapital’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4M Hold
2,500,000
– – 1.01% 12
2025
Q4 		$16.1M Hold
2,500,000
– – 1.67% 10
2025
Q3 		$14M Buy
+2,500,000
New +$10.8M 1.82% 10

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Samsara BioCapital's AQST Position: Q1 2026 in Review

Samsara BioCapital held its Aquestive Therapeutics (AQST) position steady in Q1 2026 at 2,500,000 shares worth $10.4M. The position accounts for 1.01% of the portfolio, ranked #12.

Samsara BioCapital first reported a position in AQST in Q3 2025 and has held it in 3 quarters since. The position peaked at $16.1M in Q4 2025. 179 funds tracked by Wall St. Rank hold AQST as of Q1 2026.

  • Samsara BioCapital held 2,500,000 shares of Aquestive Therapeutics worth $10.4M as of Q1 2026.
  • Samsara BioCapital left its Aquestive Therapeutics share count unchanged in Q1 2026.
  • Aquestive Therapeutics made up 1.01% of Samsara BioCapital's portfolio in Q1 2026, its #12 holding.
  • Samsara BioCapital first reported a position in Aquestive Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Samsara BioCapital's Aquestive Therapeutics position peaked at $16.1M in Q4 2025.
  • 179 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q1 2026.

Based on Samsara BioCapital's 13F filing for Q1 2026, filed 15 May 2026.